Close Menu

NEW YOK (GenomeWeb) – Caris Life Sciences said today that it has raised $150 million in growth capital through senior secured debt and convertible notes from TPG Sixth Street Partners (TSSP).

The Irving, Texas-based company said it intends to use the proceeds to launch new cancer profiling services, expand its commercial organization, increase the capacity of its clinical and R&D laboratory, grow the capabilities of its biopharmaceutical business, enforce its patents, and pursue other strategic corporate initiatives.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Jun
13

Ribosomal ribonucleic acid (rRNA) accounts for up to 99 percent of the total RNA depending on the cell type. 

Jun
18
Sponsored by
ArcherDX

This webinar will discuss background and clinical genomics of NTRK fusion detection in cancer. NTRK fusions are the focus of new therapeutic options, but clonal and subclonal lesions are notoriously difficult to detect. 

Jun
19

This webinar will discuss cell-free DNA prenatal screening in the era of genome-wide sequencing and factors influencing the clinical utility of expanded noninvasive prenatal testing (NIPT) menus.